Friday, January 18, 2019 1:50:54 PM
- if we look back at all the challenges that OWCP has had and still OWCP has managed to get their products tested in some of the most respected hospitals in Israel,...
- and kept at doing the necessary work to receive patents
- and hired on and joined work with some top level researchers and scientists that hold patents and brought public companies forward with substantial buyouts.
so we don't really know that there are no II's (institutional investors).
my WAG is if OWCP approached II's with their (OWCP's scientific and research) data and it was seriously reviewed for its potential as the CBD market opens,...II's would have invested in this ground floor opportunity and just wait it out.
granted they as institutional investors would have privy information from OWCP, the company, that we, the retail investor, would not. but that is how it works. angel investors and other institutions get that privilege with an NDA signed.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM